

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR 09/098,758 DUVALL 06/17/98 T 2543-28-93 **EXAMINER** IM22/0831 GERALD K WHITE MULCAHY, P MORTON INTERNATIONAL ART UNIT PAPER NUMBER 100 NORTH RIVERSIDE PLAZA CHICAGO IL 60606-1596 1713 DATE MAILED: 08/31/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Y	
Office Action Summary	Application No.	Applicant(s)
	09/098,758	DUVALL, TOD C.
	Examiner	Art Unit
	Peter D. Mulcahy	1713
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.		
 Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Status 		
1) Responsive to communication(s) filed on 19 May 2000.		
	s action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4) Claim(s) <u>1-3 and 6-11</u> is/are pending in the application.		
4a) Of the above claim(s) 10 and 11 is/are with	drawn from consideration.	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-3 and 6-9</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claims are subject to restriction and/or	election requirement.	
Application Papers		
9) The specification is objected to by the Examine	er.	
10) The drawing(s) filed on is/are objected to		
11) The proposed drawing correction filed on is: a) approved b) disapproved.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. § 119		
13) ☐ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d).
a) ☐ All b) ☐ Some * c) ☐ None of the CERTIFIED copies of the priority documents have been:		
1. received.	. / O . : 131	
2. received in Application No. (Series Code		
3. received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).		
* See the attached detailed Office action for a list of the certified copies not received.		
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).		
Attachment(s)		
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 1 	19) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)

Serial No. 09/098,758

Art Unit 1713

Claims 1-3 and 6-9 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Bae et al.

The rejection as set forth under 35 U.S.C. § 103(a) in Paper No. 5 is deemed proper and is herein repeated.

Applicants' arguments have been fully considered but have been deemed to be not persuasive.

Applicants argue that the Bae reference teaches the incorporation of a zinc chloride and a latent mercaptan in a halogen containing polymer composition. Applicants allege that this is patentably distinct from the instantly claimed invention in that the claimed composition incorporates a free mercaptan rather than a latent mercaptan. This is not persuasive. It is unclear to the Examiner as to exactly how a free mercaptan is patentably distinct from a latent mercaptan. Furthermore, the mercaptan compounds as shown throughout the specification appear to be the same as those shown in the disclosure of Bae. As such, the claims are rendered unpatentable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter D. Mulcahy, whose telephone number is (703) 308-2449. The examiner can normally be reached on Tuesday through Friday from 7:30 A.M. to 6:00 P.M.

Serial No. 09/098,758

Art Unit 1713

The fax telephone number for this group is (703) 305-3599.

Any inquiry of general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-2351.

P. Mulcahy:cdc August 29, 2000

> PETER D. MULCAHY PRIMARY EXAMINER GROUP 1500